Mammoth Biosciences: Elaine Sun, Ted Tisch, Adriana Dantas Lemberg, Dimitrios Zisoulis
Gene editing company Mammoth Biosciences this week announced multiple executive appointments. Elaine Sun has been named chief operating officer and CFO. She joins Mammoth from Halozyme Therapeutics, where she served as senior VP and CFO. Prior to that she was CFO and chief strategy officer at SutroVax (now Vaxcyte). She has also served as managing director at Evercore Partners and Merrill Lynch. She holds a B.A. from Wellesley College and an MBA from Harvard Business School.
Current COO Ted Tisch will assume the role of chief agility officer.
Mammoth also named Adriana Dantas Lemberg as VP of product management, and Dimitrios Zisoulis as VP of genome engineering. Dantas Lemberg previously held roles in product development, marketing, and sales at Roche and Becton Dickinson, with a particular focus on point-of-need diagnostics. Zisoulis most recently served as VP of drug discovery at Locanabio, and brings experience in gene therapy and drug development.
Delfi Diagnostics: Michaela Hart, Paul Sheives
Delfi Diagnostics, a developer of liquid biopsy tests for early cancer detection, has appointed Michaela Hart as VP of regulatory, quality, and lab operations, and Paul Sheives as VP of government relations and reimbursement.
Hart was previously VP of quality systems and compliance for Roche Molecular Solutions. She has also previously served as VP of quality management and regulatory affairs for Roche Sequencing USA, and VP of molecular operations and quality assurance for Veracyte.
Sheives most recently served as senior director of health policy and reimbursement for Roche Diagnostics. He also previously held leadership roles at the American Clinical Laboratory Association and the Biotechnology Innovation Organization.
Strata Oncology: Sundu Brahmasandra
Strata Oncology appointed Sundu Brahmasandra as chief operating officer. Brahmasandra previously served as president and COO of NeuMoDx Molecular, and later as vice president and head of operations and product management at Qiagen, after that company acquired NeuMoDx. He also cofounded HandyLab, a developer and manufacturer of molecular diagnostic assays and automation platforms, which was acquired by BD Diagnostics, where he then served as vice president of R&D assay development.
Brahmasandra holds a Ph.D. in chemical engineering from the University of Michigan College of Engineering and a bachelor's degree in chemical engineering from the Indian Institute of Technology, Madras.
For additional recent items on executive appointments and promotions in omics and molecular diagnostics, please see the People in the News page on our website.